155 related articles for article (PubMed ID: 34793589)
1. ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer.
Hua T; Wang RM; Zhang XC; Zhao BB; Fan SB; Liu DX; Wang W
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34793589
[TBL] [Abstract][Full Text] [Related]
2. Novel gene signatures for prognosis prediction in ovarian cancer.
Bao M; Zhang L; Hu Y
J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642
[TBL] [Abstract][Full Text] [Related]
3. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
5. Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer.
Yang F; Gao B; Chen W; Du E; Liang Y; Hu X; Yang X
Medicine (Baltimore); 2018 Oct; 97(41):e12364. PubMed ID: 30313031
[TBL] [Abstract][Full Text] [Related]
6. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
Qiu PY; Deng XH; Li L
Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
[TBL] [Abstract][Full Text] [Related]
7. A Novel Platinum Resistance-Related Immune Gene Signature for Overall Survival Prediction in Patients with Ovarian Cancer.
Zhou C; Ma J; Luo W; Hu J; Chen J; Liang S; He S
Biochem Genet; 2024 Feb; 62(1):112-124. PubMed ID: 37270714
[TBL] [Abstract][Full Text] [Related]
8. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
9. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
10. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
11. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
12. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
13. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
14. Identification of a glycolysis-related gene signature for survival prediction of ovarian cancer patients.
Zhang D; Li Y; Yang S; Wang M; Yao J; Zheng Y; Deng Y; Li N; Wei B; Wu Y; Zhai Z; Dai Z; Kang H
Cancer Med; 2021 Nov; 10(22):8222-8237. PubMed ID: 34609082
[TBL] [Abstract][Full Text] [Related]
15. Identification of dysregulated miRNAs-genes network in ovarian cancer: An integrative approach to uncover the molecular interactions and oncomechanisms.
Kadkhoda S; Darbeheshti F; Tavakkoly-Bazzaz J
Cancer Rep (Hoboken); 2020 Dec; 3(6):e1286. PubMed ID: 32886452
[TBL] [Abstract][Full Text] [Related]
16. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
17. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian Cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract][Full Text] [Related]
18. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.
Tabassum A; Samdani MN; Dhali TC; Alam R; Ahammad F; Samad A; Karpiński TM
J Mol Med (Berl); 2021 Sep; 99(9):1293-1309. PubMed ID: 34047812
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
